title: The proarrhythmic risk of cell therapy for cardiovascular diseases.
abstract: Stem cell therapy is an emerging therapeutic approach for the treatment of cardiovascular diseases. Experimental studies have demonstrated that different types of stem cells, including bone marrow-derived cells, mesenchymal stem cells, skeletal myoblasts, and cardiac progenitor cells and embryonic stem cells, can improve cardiac function after myocardial injuries. Nevertheless, the potential proarrhythmic risk after stem cell transplantation remains a major concern. Several mechanisms, including the immaturity of electrical phenotypes of the transplanted cardiomyocytes, poor cell-cell coupling and cardiac nerve sprouting, may contribute to arrhythmogenic risk after stem cell transplantation. This review summarizes the potential theoretical arrhythmogenic mechanisms associated with different types of stem cells for the treatment of cardiovascular diseases. Nevertheless, current experimental and clinical data on the proarrhythmic risk for different types of stem cell transplantation are limited, and await further experimental and clinical investigation.
authors: Cardiology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, HKSAR, China.
authors: Yuan
authors: Y
authors: Liu
authors: Hung-Fat
authors: HF
authors: Tse
mesh_terms: D000328:Adult; D053687:Adult Stem Cells / Q000166:cytology / Q000637:transplantation; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000209:etiology*; D002318:Cardiovascular Diseases / Q000503:physiopathology / Q000628:therapy*; D002454:Cell Differentiation; D006333:Heart Failure / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D032383:Myocytes, Cardiac / Q000166:cytology / Q000637:transplantation*; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014182:Transplantation, Autologous